An oral CXCR4 antagonist, X4P-001, improves the efficacy of checkpoint inhibitor therapy and modulates tumor infiltrating immune cells by disrupting the CXCL12-CXCR4 axis [127]. Here, CXCR4 is linked to neoplasm.